Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland [3]

Journal of the American Geriatrics Society

Volumn 55, Issue 11, 2007, Pages 1886-1887

  Virta, Lauri ^a   Viramo, Petteri ^b  

^a SOCIAL INSURANCE INSTITUTION   (Finland)

^b OULU DEACONESS INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CONFIDENCE INTERVAL; DISEASE SEVERITY; EVALUATION; FINLAND; GROUPS BY AGE; HUMAN; INCIDENCE; INSTITUTIONAL CARE; LETTER; ORGANIZATION AND MANAGEMENT; POPULATION RESEARCH; POPULATION RISK; REGISTER; REIMBURSEMENT; VALIDITY;

ADULT; AGE FACTORS; AGED; ALZHEIMER DISEASE; CHOLINERGIC AGENTS; DOPAMINE AGENTS; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEMANTINE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NOOTROPIC AGENTS; REGISTRIES; SEX FACTORS;

EID: 35748943478     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01383.x     Document Type: Letter

References (1)

1. Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000 54 (Suppl 5) : 10 15.